{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T03:37:31Z","timestamp":1767670651722,"version":"3.48.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"published-print":{"date-parts":[[2025,7]]},"abstract":"\n Background<\/jats:title>\n People with relapsing forms of multiple sclerosis (PwRMS) treated with ofatumumab, a fully human anti-CD20 monoclonal antibody, can experience local\/systemic injection-related reactions (IRRs). However, data on the occurrence and management of local\/systemic IRRs in real-world clinical settings are limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aimed to better understand clinicians\u2019 perspectives regarding occurrence and management of local\/systemic IRRs among PwRMS treated with ofatumumab in clinical practice.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A panel of US-based neurologists and advanced practice providers experienced with ofatumumab therapy in PwRMS participated in a three-round online modified Delphi study. In round 1, participants completed a demographics survey and Delphi questionnaire on IRR management. In round 2, they attended a live webinar to obtain feedback on round 1 results. In round 3, they reviewed round 1 and 2 feedback and provided their final responses.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Forty participants (neurologists,\n n<\/jats:italic>\n \u2009=\u200931; nurse practitioners,\n n<\/jats:italic>\n \u2009=\u20095; and physician assistants,\n n<\/jats:italic>\n \u2009=\u20094) completed all three rounds. Participants strongly agreed that local\/systemic IRRs, regardless of severity, were unlikely with ofatumumab. Pre-\/post-treatment of systemic IRRs was not uniformly required.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This study gives health care providers insight into the potential occurrence and management of IRRs with ofatumumab in the clinical practice setting.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/20552173251355677","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T02:52:36Z","timestamp":1751597556000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Delphi panel to understand the real-world occurrence and management of ofatumumab injection-related reactions among healthcare providers of people with relapsing multiple sclerosis"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-0714","authenticated-orcid":false,"given":"Shiv","family":"Saidha","sequence":"first","affiliation":[{"name":"Division of Neuroimmunology and Neurological Infections, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1799-8623","authenticated-orcid":false,"given":"John","family":"Kramer","sequence":"additional","affiliation":[{"name":"Vanderbilt Multiple Sclerosis Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Brown","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Brewer","sequence":"additional","affiliation":[{"name":"PRECISION AQ, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelyn W","family":"Chou","sequence":"additional","affiliation":[{"name":"PRECISION AQ, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlon","family":"Graf","sequence":"additional","affiliation":[{"name":"PRECISION AQ, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7845-0704","authenticated-orcid":false,"given":"Rozanne","family":"Wilson","sequence":"additional","affiliation":[{"name":"PRECISION AQ, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2091-8201","authenticated-orcid":false,"given":"Benjamin M","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01650-7"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00518-0"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000323216"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03110.x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19042203"},{"key":"e_1_3_3_8_2","unstructured":"Fitch K Bernstein SJ Aguilar MD et al. The RAND\/UCLA appropriateness method user\u2019s manual https:\/\/www.rand.org\/pubs\/monograph_reports\/MR1269.html (2001 accessed 1 February 2024)."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221079731"},{"key":"e_1_3_3_10_2","unstructured":"Genentech I. OCREVUS prescribing information https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf (2023 accessed 30 November 2023)."},{"key":"e_1_3_3_11_2","unstructured":"TG Therapeutics Inc. Briumvi prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761238s000lbl.pdf (2022 accessed 30 November 2023)."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032829"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.5662\/wjm.v11.i4.116"}],"container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173251355677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552173251355677","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173251355677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T03:33:27Z","timestamp":1767670407000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552173251355677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/20552173251355677"],"URL":"https:\/\/doi.org\/10.1177\/20552173251355677","relation":{},"ISSN":["2055-2173","2055-2173"],"issn-type":[{"type":"print","value":"2055-2173"},{"type":"electronic","value":"2055-2173"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"20552173251355677"}}